Clin2
NCT07094763Possibly a fitRecruiting

Tenecteplase for posterior stroke 4.5-24 hours after onset

Acute Ischemic Stroke

Treatments studied

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests a clot-busting drug called tenecteplase for people who had a stroke affecting the back part of the brain (posterior circulation). It may be an option if you can get treatment between 4.5 and 24 hours after symptoms started.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
406 people
Ages
18 years to 100 years
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • Your stroke is in the back of the brain (posterior circulation), confirmed by imaging.
  • You can receive treatment between 4.5 and 24 hours after symptoms began (or from when you were last seen well).
  • Your stroke symptoms are at least moderately severe (NIHSS score over 3).
  • You have not had recent bleeding, major surgery, or certain blood thinners.
  • You have not had a prior stroke, heart attack, or head injury in the last 3 months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07168278Not yet recruiting· Phase 3
Tenecteplase vs standard care for large vessel stroke 4.5-24 hours

This trial tests if a clot-busting drug called tenecteplase can improve outcomes for people with a large vessel stroke when treatment starts 4.5 to 24 hours after symptoms began, and when a mechanical clot removal procedure (EVT) is not available. You would receive tenecteplase or standard medical care to see which works better.

Hefei, Anhui
NCT07361302Recruiting· Phase 3
Tenecteplase for stroke after 4.5 hours

This trial tests a clot-dissolving medicine called tenecteplase for people who had a stroke more than 4.5 hours ago. It may help you recover if given later than usual.

Buenos Aires
NCT07606807Recruiting· Phase 3
New clot-busting medication for stroke in the extended time window

This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.

Guangzhou
NCT07475949Not yet recruiting· Phase 3
Stroke treatment for unknown wake-up time

This trial tests a clot-busting drug for people who had a stroke but don't know when it started, like waking up with symptoms. It may help reduce disability if given soon after noticing symptoms.

Nanning, Guangxi
NCT07540416Not yet recruiting· Phase 3
Tenecteplase for Recent Stroke Using Special Brain MRI Patterns

This trial tests whether tenecteplase (a clot-busting medication) can help patients who have had a stroke within 4.5 to 9 hours and show a specific pattern on brain MRI called DWI-FLAIR mismatch, which suggests the brain tissue may still be salvageable.

Zhengzhou, Henan
NCT07092709Recruiting· Phase 3
Tenecteplase for stroke patients who recently took blood thinners

This trial tests if the clot-busting drug tenecteplase is safe and effective for people having an ischemic stroke who have recently taken blood thinners (DOACs). If you qualify, you may receive either tenecteplase or a placebo within 24 hours of your last known well time.

Guangzhou, Guangdong

Hear when a new Acute Ischemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.